Company / Cash & Equivalents
Coherus Oncology, Inc. Cash & Equivalents History
FY2014-FY2019 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$177.7M
FY2019
5-year range
$39.6M / $177.7M
FY2015-FY2019
Trend
+145.5%
vs FY2018
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Cash & Equivalents returned to growth in FY2019 after 2 years of decline, reaching $178M.
Based on SEC 10-K filings.
$178M in FY2019 with a 5-year CAGR of +65.0%.
Improved from $127M to $178M over the past 2 years.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- +5.7%
- 5-Year CAGR
- +65.0%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of +65.0%, indicating consistent growth.
- In FY2019, cash & equivalents increased 145.5% year-over-year.
- Lowest cash & equivalents in the period was in FY2014.
Company context
Key Data Points
- Altman Z-Score -0.49 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2019 | $177.7M | +145.5% |
| FY2018 | $72.4M | -43.0% |
| FY2017 | $126.9M | -15.6% |
| FY2016 | $150.4M | +280.2% |
| FY2015 | $39.6M | +171.9% |
| FY2014 | $14.5M | - |
As of FY2019 · SEC 10-K · Updated Jun 24, 2026